<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911028-0132</DOCNO><DOCID>911028-0132.</DOCID><HL>   Financing Business:   Duramed Lender Balks on Plan</HL><DATE>10/28/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C16</SO><CO>   DRMD PRBK</CO><MS>FINANCIAL (FIN)CONSUMER NON-CYCLICAL (NCY)</MS><IN>EASTERN U.S. BANKS (BAE)ALL REGIONAL BANKS (BAR)ALL BANKS, BANKING NEWS AND ISSUES (BNK)DRUG MANUFACTURERS (DRG)</IN><NS>FINANCING AGREEMENTS (FNC)</NS><RE>NORTH AMERICA (NME)OHIO (OH)UNITED STATES (US)</RE><LP>   CINCINNATI -- Duramed Pharmaceuticals Inc. said itsprincipal lender, Provident Bancorp Inc., decided not tocomplete its proposed refinancing of Duramed.   The Cincinnati bank had proposed exchanging $7 million ofdebt for 7,850,000 Duramed common shares. The scuttled swapmeans Duramed will not be able to complete a proposedsettlement of claims from unsecured creditors. The drugcompany had agreed to make partial cash payments and to offeroptions on common stock to unsecured creditors.</LP><TEXT>   Duramed, which has been financially troubled because ofthe recall of all of its generic drugs in the past year, saidit will look for financing alternatives.</TEXT></DOC>